Published on 18 May 2023 on Simply Wall St. via Yahoo Finance

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To Be

Today is shaping up negative for Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon.

After the downgrade, the consensus from Atara Biotherapeutics' six analysts is for revenues of US$26m in 2023, which would reflect a concerning 55% decline in sales compared to the last year of performance. Losses are supposed to balloon 24% to US$2.72 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$21m and losses of US$2.88 per share in 2023. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

See our latest analysis for Atara Biotherapeutics